Court of Appeals for the Eleventh Circuit September 6, 2002, 02-10151 (Pharmaceutical Research & Manufacturers of America v. Meadows)
Also known as
United States · · · 06-09-2002
[PUBLISH]
IN THE UNITED STATES COURT OF APPEALS
FOR THE ELEVENTH CIRCUIT
________________ FILED
U.S. COURT OF APPEALS
ELEVENTH CIRCUIT
No. 02-10151 September 6, 2002
________________ THOMAS K. KAHN
D. C. Docket No. 01-00356 CV-4-WS CLERK
PHARMACEUTICAL RESEARCH AND MANUFACTURERS
OF AMERICA,
Plaintiff-Appellant,
versus
RHONDA M. MEADOWS,
BOB SHARPE,
Deputy Secretary of Medicaid Agency for Health
Care Administration of the State of Florida,
Defendants-Appellees.
_______________________
Appeal from the United States District Court for the
Northern District of Florida
_______________________
(September 6, 2002)
Before BIRCH, MARCUS and CUDAHY*, Circuit Judges.
*
Honorable Richard D. Cudahy, U.S. Circuit Judge for the Seventh Circuit, sitting by designation.
CUDAHY, Circuit Judge:
The Florida legislature recently added another chapter in the ongoing efforts
of states to hold down their Medicaid drug costs. The new Florida law enacted
changes in its Medicaid program by creating a “preferred drug formulary” (also
referred to as a “preferred drug list”), which exempts certain Medicaid-eligible
drugs from a “prior authorization” requirement. If a drug is not on the preferred
list, the prescribing doctor must call a state pharmacist to obtain approval of its use.
In the course of this procedure, the pharmacist informs the doctor of the
availability of other drugs (usually on the preferred drug list) that allegedly have
comparable therapeutic value but are less expensive. The actual phone calls tend
to be relatively brief (usually less than 10 minutes in length), and approval of the
prescribing doctor’s first-choice drug is guaranteed in 100 percent of all cases,
provided only that he or she make the telephone call. During the first three months
of the program, approximately 55 percent of all these calls have resulted in a
change of the prescription to a drug on the preferred drug list.
Read the full text
This document is published by courtlistener.com.
Moonlit adds the citation network, article-level links and cross-references, which are available to search for free.
Sign in to Moonlit